Virchows Arch (2017) 471:809–813 DOI 10.1007/s00428-017-2222-z BRIEF REPORT Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey 1 1 2 3 Zandra C. Deans & Hannah Williams & Elisabeth M. C. Dequeker & Cleo Keppens & 4 5 6 6 Nicola Normanno & Ed Schuuring & Simon J. Patton & Melanie Cheetham & 7 8,9 Rachel Butler & Jacqueline A. Hall & On behalf of IQN Path ASBL Received: 18 April 2017 /Revised: 6 July 2017 /Accepted: 14 August 2017 /Published online: 25 August 2017 The Author(s) 2017. This article is an open access publication Introduction several advantages: in the absence of suitable or sufficient tissue biopsy, it yields material for molecular analysis, can demonstrate Molecular biomarker analysis for the personalised treatment molecular resistance to targeted treatment and is an alternative to of non-small cell lung cancer (NSCLC) and colorectal cancer invasive tissue sampling . Plasma ctDNA analysis may also (CRC) is becoming more common, due to the number and prove useful in cases of intra- and inter-tumour heterogeneity availability of molecular targets for predictive biomarker test- . With formal approval from the European Medicine Agency ing
Virchows Archiv – Springer Journals
Published: Aug 25, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud